EUCTR2018-000579-34-NL进行中（未招募）1 期
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myeloproliferative Neoplasms) - MANIFEST
Constellation Pharmaceuticals, Inc., a Morphosys Company0 个研究点目标入组 297 人开始时间: 2018年11月6日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 297
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Prior JAKi Arm 1 and Add-on to JAKi Arm 2:
- •1. Adult (aged = 18 years)
- •2. Patients with confirmed diagnosis of MF who meet all of the following criteria:
- •a. Dynamic International Prognostic Scoring System (DIPSS; see Appendix 3) risk category of intermediate-2 or higher
- •b. Platelet count = 75 x 109/L without the assistance of thrombopoietic factors or transfusions
- •c. ANC = 1 x 109/L without the assistance of granulocyte growth factors
- •d. Spleen volume of =450 cm3 by CT or MRI for Cohorts 1B and 2B OR RBC TD (defined as an average of =2 units of RBC transfusions per month [total of = 6 RBC transfusions over the 12 wks] prior to enrollment) for Cohorts 1A and 2A
- •e. Peripheral blood blast count <10%
- •f. At least 2 symptoms measurable (score = 1) using the MFSAF v4.0
- •g. Monotherapy Arm (Arm 1) patients only: Previously treated with a JAKi and be intolerant, resistant, refractory or lost response to the JAKi; have not received the JAKi within 2 weeks prior to start of study drug, or are ineligible to be treated with a JAKi
- •h. Combination Arm (Arm 2) patients only: Must have received ruxolitinib for at least 6 months and be on a stable ruxolitinib dose for a minimum 8 weeks (prior to start of study drug)
- •3. ECOG performance status = 2
- •4. Serum direct bilirubin = 1.5 x ULN (upper limit of normal)
- •5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 2.5 x ULN. The AST and /or ALT may be elevated up to 5 x ULN if the elevation can be reasonably ascribed to liver involvement
- •6. Calculated or measured creatinine clearance (CrCl) = 45 ml/min (either measured or estimated by the Cockcroft-Gault formula)
- •7. Patients must have fully recovered from major surgery and from the acute toxic effects of prior chemotherapy and radiotherapy (residual CTCAE grade 1 toxicity, e.g., grade 1 peripheral neuropathy, and residual alopecia are allowed)
- •8. Male and WOBCP and partners of patients with reproductive potential must agree to use highly effective contraceptive methods while on study therapy and for 94 days after the last dose of pelabresib for male patients and male partners of female patients, and for 184 days after the last dose of study drug for WOBCP and female partners of male patients. NOTE: Male patients should be informed of the risk of testicular toxicity and provided with adequate advice regarding sperm preservation
- •JAKi Naive Arm 3:
- •1. Adult (aged = 18 years)
- •2. Patients with confirmed diagnosis of MF who meet all of the following criteria:
- •a. DIPSS (see Appendix 3) risk category of intermediate-2 or higher
- •b. Platelet count = 100 x 109/L without the assistance of thrombopoietic factors or transfusions
- •c. ANC = 1 x 109/L without the assistance of granulocyte growth factors
- •d. Spleen volume of = 450 cm3 by CT/MRI
- •e. Peripheral blood blast count <10%
- •f. At least 2 symptoms measurable (score = 3) or a total score of = 10 using the MFSAF v4.0
- •g. No prior treatment with JAKi allowed
- •3. ECOG performance status = 2
- •4. Life expectancy of >24 weeks
- •5. Serum direct bilirubin < 2.0 x ULN
- •6. AST and ALT = 2.5 x ULN. The AST and /or ALT may be elevated up to 5 x ULN if the elevation can be reasonably ascribed to liver involvement
- •7. Calculated or measured CrCl = 45 ml/min (either measured or estimated by the Cockcroft-Gault formula)
- •8. Patients with a history of transfusions must have a documented transfusion record during the 12 weeks prior to the first dose of study drug
- •9. Patients must have fully recovered from major surgery and from t
排除标准
- •Prior JAKi Arm 1 and Add-on to JAKi Arm 2:
- •1. Patients in Cohorts 1B and 2B only: Patients who have had prior splenectomy
- •2. Patients in Cohorts 1B and 2B only: Patients who have had splenic irradiation within 3 months of starting study drug
- •3. Current known active or chronic infection with HIV, Hepatitis B or Hepatitis C.
- •4. Patients with active clinically significant infection will not be eligible for enrollment until recovery for at least 2 weeks prior to the first dose of study drug.
- •5. Patients with anemia from iron deficiency, B12 and folate deficiencies, hemolytic anemia, or infection
- •6. Patient with a major bleeding event causing a decrease in hemoglobin of = 2g/dL or leading to transfusion of = 2 units of packed red cells in the last 6 months prior to enrollment
- •7. Patients with Child-Pugh Class B or C
- •8. GI function or GI disease that could significantly alter the absorption of pelabresib and/or ruxolitinib
- •9. Impaired cardiac function or clinically significant cardiac diseases
- •10. Ongoing uncontrolled hypertension despite maximal antihypertensive treatment
- •11. Any other concurrent severe and/or uncontrolled concomitant medical condition that in the opinion of the investigator could compromise participation in the study or analysis of study data
- •12. Systemic anti-cancer treatment (other than ruxolitinib for the Combination Arm [Arm 2]; see inclusion criterion #2) other than hydroxyurea and anagrelide less than 2 weeks (or 5 half-lives, whichever is longer) before the first dose of pelabresib.
- •13. Any investigational agent >2 weeks (or 5 half-lives) before the first dose of pelabresib
- •14. Prior treatment with a BET inhibitor
- •15. Hematopoietic growth factor (granulocyte growth factor, erythropoiesis stimulating agent, thrombopoietin mimetic) or androgenic steroids less than 4 weeks before the first dose of study drug
- •16. Patients in the Combination Arm (Arm 2) who are receiving treatment with fluconazole
- •17. Systemic corticosteroids at daily doses = 10 mg of oral prednisone or equivalent within 2 weeks before the first dose of study drug.
- •(For further exclusion criteria for Arm 1 & 2 and details please refer to the protocol)
- •JAKi Naive Arm 3:
- •1. Prior treatment with a BET inhibitor
- •2. Patients who have had a prior splenectomy
- •3. Patients who have had splenic irradiation within 3 months of starting study drug
- •4. Current known active or chronic infection with HIV, Hepatitis B or Hepatitis C
- •5. Patients with active clinically significant infection will not be eligible for enrollment until
- •recovery for at least 2 weeks prior to the first dose of study drug
- •6. Patients with anemia from iron deficiency, B12 and folate deficiencies, hemolytic anemia or infection
- •7. Patient with a major bleeding event causing a decrease in Hgb of = 2g/dL or leading to transfusion of =2 units of packed red cells in the last 6 months prior to enrollment
- •8. Patients with Child-Pugh Class B or C
- •9. Impairment of GI function or GI disease that could significantly alter the absorption of pelabresib and/or ruxolitinib
- •10. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption or patients with hypersensitivity to any ingredient in the formulation of ruxolitinib
- •11. Patients who have or have had PML
- •12. Impaired cardiac function or clinically significant cardiac diseases
- •13. Ongoing uncontrolled hypertension despite maximal antihypertensive treatment
- •14. Any other concurrent severe
研究者
相似试验
招募中
2 期
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myeloproliferative Neoplasms)NL-OMON52821Constellation Pharmaceuticals12
进行中（未招募）
1 期
A clinical study to investigate the safety and efficacy of CPI-0610 in patients with and essential thrombocythemiaMyeloproliferative Neoplasms (Myelofibrosis and Essential Thrombocythemia)MedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10015494Term: Essential thrombocythemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000579-34-PLConstellation Pharmaceuticals, Inc.297
进行中（未招募）
1 期
A clinical study to investigate the safety and efficacy of CPI-0610 in patients with myelofibrosis and essential thrombocythemiaEUCTR2018-000579-34-GBConstellation Pharmaceuticals, Inc.297
进行中（未招募）
1 期
A clinical study to investigate the safety and efficacy of CPI-0610 in patients with myelofibrosis and essential thrombocythemiaMyeloproliferative Neoplasms (Myelofibrosis and EssentialThrombocythemia)MedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10015494Term: Essential thrombocythemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000579-34-BEConstellation Pharmaceuticals, Inc., a Morphosys Company297
进行中（未招募）
1 期
A clinical study to investigate the safety and efficacy of CPI-0610 in patients with myelofibrosismyelofibrosisEUCTR2018-000579-34-ITConstellation Pharmaceuticals, Inc.271